Vistin Pharma ASA Celebrates Record EBITDA and Financial Growth Amidst Industry Challenges
Vistin Pharma ASA reported a 14% revenue increase and 48% EBITDA growth in Q1 2025, solidifying its position as a leader in the pharmaceutical industry.
3 minutes to read